Prostate cancer incidence rates have increased by 3% annually since 2014, with advanced-stage diagnoses rising by 4.6% to 4.8% per year. Mortality rate declines have slowed to 0.6% annually, with ...
FDA cleared Titan Prime, a next-generation IPP, emphasizing improved flaccid flexibility intended to enhance comfort and concealability for erectile dysfunction patients. Approval of generic Ga-68 ...
Sender Herschorn, BSc, MDCM, FRCSC, discusses a subgroup analysis of the COURAGE trial showing that vibegron provided comparable efficacy and favorable safety in men aged 75 years and older with ...
In this episode, Anup A. Vora, MD, discusses patient selection for focal therapy in localized prostate cancer, the role of precision medicine, and how advanced practice providers are helping deliver ...
Louise Emmett, MD, PhD, MBChB, FRACP, discusses findings from the phase 1 AcTION trial, which evaluated the safety and preliminary activity of 225Ac-PSMA-617 in patients with metastatic ...
In this episode, Amy Pearlman, MD, sits down with Alan J. Wein, MD, PhD (hon), FACS, to discuss how the field of urology has evolved and how clinicians can thoughtfully evolve alongside it. Jonathan ...
Cycling has multiple benefits, and steps can be taken to prevent genitourinary injury. Bicycling across the globe is increasing as a means of exercise and transportation. Clinicians need to be ...
The following FAQs highlight key recommendations and practical takeaways from the 2026 AUA/SUO Advanced Prostate Cancer Guideline. Two overarching themes define the 2026 amendment: the consolidation ...
A new analysis supports return to widespread screening. A reevaluation of the tradeoffs of prostate cancer screening using the most recent data should rewrite the negative narrative associated with ...
The updated guidelines focus on appropriate pre-procedure evaluation and novel surgical enhancements, according to Matthew D. Houlihan, DO, and Tobias S. Köhler, MD, MPH. AUA guidelines on benign ...
Researchers at the Mayo Clinic report that they have developed a legitimate penile traction therapy device for men with Peyronie’s disease that may work when used for just 30 to 90 minutes daily.
The Altaviva device offers a minimally invasive treatment for urge urinary incontinence, with patients returning home with therapy activated. It features a 15-year battery lifespan, MRI compatibility, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results